Genmab stock reacts to fresh DARZALEX sales update
Genmab (CPSE:GMAB) drew fresh attention after reporting third quarter 2026 DARZALEX net trade sales of US$4.239b, including US$2.528b from the U.S. market and US$1.711b internationally.
Investors have responded positively, with Genmab’s share price up 12.48% over the past month and 37.22% over 90 days. The 1-year total shareholder return of 27.96% and weaker 5-year total shareholder return indicate strong recent momentum following a tougher longer stretch.
Scan how Genmab compares to other potential movers in its space by checking a curated 125 healthcare AI stocks aligned with similar healthcare and biotech themes.
Genmab now trades at a steep implied discount to one valuation estimate and a modest gap to analyst targets. Is the recent share price surge a catch up, or a signal the market still sees real risk ahead?
Most Popular Narrative: 2% Overvalued
Genmab closed at DKK2,542, just above the central narrative fair value of DKK2,500, which frames the recent DARZALEX driven rally as slightly ahead of that model.
Strong late-stage pipeline progress, including positive Phase III results for epcoritamab (EPKINLY) and expansion of Rina-S programs, is viewed as positioning Genmab to benefit from the growing global burden of cancer and rising demand for innovative biologic therapies.
See why 68 investors see Genmab as 2% overvalued.
Result: Fair Value of DKK2,500 (OVERVALUED)
Still, Genmab’s heavy reliance on DARZALEX royalties, along with the chance of pipeline setbacks or trial disappointments, could quickly challenge this “only 2% overvalued” narrative.
Find out about the key risks to this Genmab narrative.
Another View: Genmab through a cash flow lens
The share price reaction around DKK2,542 only tells part of the story. On Simply Wall St’s DCF model, Genmab screens as trading at a large discount to an estimated future cash flow value of DKK5,448.84 per share, suggesting the market is pricing in sizeable execution and pipeline risks. Which version of Genmab do you think is closer to reality?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Genmab for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 200 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Mixed messages in the Genmab story today. Focus on the numbers, not the noise, to pressure test your own thesis with 2 key rewards and 3 important warning signs.
Looking for more Genmab sized investment ideas?
Do not stop with Genmab. Use this momentum to refresh your watchlist with fresh, data driven ideas that could reshape how you allocate capital next.
- Target potential mispricings by scanning a focused group of 200 high quality undervalued stocks that combine solid fundamentals with room for sentiment to catch up.
- Strengthen your income stream by reviewing a curated set of 219 dividend fortresses that aim to balance yield with balance sheet resilience.
- Dial down portfolio stress by filtering for 231 resilient stocks with low risk scores designed to prioritize steadier financial profiles over headline grabbing swings.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com